Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Our strategy is based on an integrated business model that has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.
Upcoming Events
May 23, 2022
H.C. Wainwright Conference
June 8, 2022
Jefferies Healthcare Conference
EC APA Update
Valneva comments on European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement
View MoreContact
Investor Relations Team
Campus Bio-Ouest6, Rue Alain Bombard
44800 Saint-Herblain, France T: +33 2 28 07 37 10 investors@valneva.com